Ambiguous Genetic Test Results Can Be Unsettling. Worse, They Can Lead to Needless Surgeries
Basser Executive Director Susan Domchek, MD, was quoted in a story on the ambiguity of certain genetic tests and how “variants of unknown significance” (VUS) can guide cancer treatments, despite a lack of evidence to support those decisions.
Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers
Basser Center Executive Director Susan Domchek, MD, discusses the complex issue of risk-reducing mastectomy in BRCA mutation carriers in an editorial for the Journal of the American Medical Association.
Blackstone COO Jonathan Gray On Giving To Education, Cancer Research
Basser Center founders Mindy and Jon Gray have a well-deserved spot on Forbes' annual list of top 50 philanthropists. "In total, Gray has given over $120 million in his lifetime, primarily to cancer research and health and education in New York City."
Evening of Storytelling Speaks to Future of Cancer Research
The Basser Center's Young Leadership Council recently hosted a storytelling event featuring personal stories from three individuals touched by BRCA mutations, which all spoke to the promising future that research will provide for future patients and the newly BRCA-positive population.
When Is It Time To Get Preventative Surgeries To Avoid Cancer?
Basser Center Executive Director Susan Domchek, MD, joins KJZZ's The Show for an episode devoted to genetic testing, preventative surgery, and raising awareness of hereditary breast cancer.
With CRISPR, Scientists Engineered Nearly 4,000 Mutations of a Breast-Cancer Gene
Using CRISPR, a team assessed 3,893 otherwise unstudied mutations of BRCA1, which normally suppresses cancerous tumors, but can be rendered ineffective when they’re mutated.
How Men Can Be Affected by the BRCA Gene, Too
Basser’s Susan Domchek, MD, and Penn Medicine patient Steven Merlin, whose participation in groundbreaking clinical trials using PARP inhibitor drugs has kept him cancer-free for six years, comment on how BRCA mutations affect men.
The club where no one has cancer — yet
Basser Young Leadership Council member Suzanne Zupello recently penned this personal piece on the importance of support communities for those with BRCA mutations for The Lily.
Centenarian Eagles Fan Becomes Social Media Star
The Basser family patriarch, Phil Basser, father to the Center's co-founder Mindy Gray and Basser Global Prize co-founder Shari Potter, is featured in the Jewish Exponent for his century of loving Philadelphia football.
Free Panel to Explore Living with Inherited Cancer Risk
The San Diego Union-Tribune reports on our upcoming panel on hereditary cancer and BRCA in La Jolla, California.
Rucaparib Induces Response in BRCA-Mutated Pancreatic Cancer
Basser Executive Director, Susan Domchek, MD, discusses the challenges of treating pancreatic cancer, the role of BRCA mutations in malignancies other than breast or ovarian cancers, and the broader role of PARP inhibitors for this patient population.
At-Home DNA Tests are Changing How Patients See Themselves
WHYY's The Pulse sat down with Dana Clark, MS, LCGC, a genetic counselor in the Basser Center, to learn how these services are affecting decisions and outlooks on health.
Pilot Program Offers Free Genetic Testing for Ashkenazi Jews to Detect Cancer Risk
Basser Executive Director, Susan Domchek, MD, explains the recently began BRCA Founder Outreach Study (BFOR) with the Cleveland Jewish News.
Ovarian Cancer Drug Shows Promise in Pancreatic Cancer Patients with BRCA Mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women, including those with BRCA1 and BRCA2 mutations, may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.
Beyond BRCA: Examining Links between Breast Cancer, Second Primary Cancer and Inherited Genetic Mutations
Rates of inherited mutations in genes other than BRCA are twice as high in breast cancer patients who have had a second primary cancer – including, in some cases, different types of breast cancer – compared to patients who have only had a single breast cancer.
The ‘Jolie Effect’ Was A Game-Changer For Breast Cancer, But It Was Just A Start
Basser Young Leadership Council Co-Chair Erika Stallings contributed this opinion piece to Huffington Post on the future of BRCA testing and on-going challenges, such as difficulties regarding access to genetic counseling and testing.
Using Telemedicine to Bring Genetic Counseling to Community Cancer Care
Genetic counseling for cancer patients has become standard of care at academic medical centers. Video and phone sessions can bring genetic counseling to patients who would not otherwise have the chance to receive it, according to a new study from the Basser Center.
PARP Drugs Help Some Breast Cancer Patients, But They’re No Magic Bullet
Forbes spoke with Susan Domchek, MD, Executive Director of the Basser Center, about how a woman with advanced breast cancer might choose among treatment options, and the latest data available on the effectiveness and safety of PARP inhibitors.
PARP-1 May be Key to Effectiveness of PARP Inhibitors, and Now Researchers Can Image It
Penn Medicine researchers, including Basser's Roger Greenberg, PhD, MD, have used CRISPR/Cas9 gene editing technology to isolate a key genetic feature that could cause resistance to PARP inhibitors in patients with ovarian cancer.